Article

Somatostatin-like immunoreactivity in the cerebrospinal fluid of aged patients with Parkinson's disease. The effect of dopatherapy.

Notre-Dame Hospital, Montreal, Canada.
Journal of the American Geriatrics Society (impact factor: 3.74). 02/1990; 38(1):19-24.
Source: PubMed

ABSTRACT Cerebrospinal fluid (CSF) somatostatin concentrations were measured in 35 aged patients with Parkinson's disease (mean age, 79.5 years) and 11 control subjects (mean age, 82.3 years). In patients with Parkinson's disease the levels of somatostatin-like immunoreactivity were lower than in controls (P less than .02); these values were lowest in the untreated group. Somatostatin-like immunoreactivity levels in the CSF tended to increase with treatment but not significantly (P = .11). Somatostatin values were not correlated to age, sex, or duration of the disease. Somatostatin concentrations tended to be lower in more severely affected patients with higher scores on the Hoehn and Yahr (P = .13) and Webster staging scales (P = .13) and lower scores on Mini-Mental State (P = .10), but without statistical significance for these correlations.

0 0
 · 
0 Bookmarks
 · 
28 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

11 control subjects
 
Cerebrospinal fluid
 
higher scores
 
Hoehn
 
lower
 
lower scores
 
Mini-Mental State
 
Parkinson's disease
 
patients
 
Somatostatin concentrations
 
somatostatin-like immunoreactivity
 
Somatostatin-like immunoreactivity levels
 
statistical significance
 
untreated group
 
Webster
 
Yahr
 

H Masson